8-K: Altimmune to Explore Pemvidutide for Alcohol Use Disorder and Alcohol-Associated Liver Disease

Altimmune, Inc. announces the pursuit of two new indications, Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD), for its lead product candidate, pemvidutide.

Summary

• Altimmune is expanding the potential use of its drug, pemvidutide, to include Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD).
• AUD is a chronic disease marked by uncontrolled drinking, often accompanied by other health issues like obesity and high blood pressure.
• Altimmune plans to initiate a Phase 2 clinical trial for pemvidutide in AUD patients in the second quarter of 2025, involving approximately 100 participants over 24 weeks.
• The AUD trial will measure changes in heavy drinking days, alcohol consumption biomarkers, and weight loss.
• ALD is a liver condition caused by excessive alcohol consumption, potentially leading to cirrhosis.
• A Phase 2 ALD trial for pemvidutide is expected to begin in the third quarter of 2025, enrolling around 100 obese subjects with ALD for 48 weeks.
• The ALD trial will assess changes in liver stiffness, alcohol consumption, and biomarkers related to liver health.

Sentiment

Score: 7

Explanation: The announcement is positive as it expands the potential use of Altimmune's lead drug candidate, but the success of the clinical trials is still uncertain.

Positives

• Expanding the indications for pemvidutide could significantly increase its market potential.
• Addressing AUD and ALD with a single drug could offer a more holistic treatment approach, given the common comorbidities.
• The planned Phase 2 trials will provide valuable data on pemvidutide's efficacy in treating these conditions.

Risks

• Clinical trials may not yield positive results, potentially halting further development for these indications.
• Regulatory approval for AUD and ALD indications is not guaranteed, even with successful trial outcomes.
• The trials are only Phase 2, and Phase 3 trials may be required which would require additional capital.

Future Outlook

Altimmune anticipates initiating Phase 2 trials for pemvidutide in both AUD and ALD, with the goal of demonstrating its efficacy in treating these conditions and potentially expanding its market reach.

Industry Context

The pharmaceutical industry is actively seeking new treatments for AUD and ALD, given the significant unmet medical need and the increasing prevalence of these conditions. Altimmune's move to explore pemvidutide for these indications aligns with this trend.

Comparison to Industry Standards

• Current treatments for AUD primarily focus on managing alcohol cravings and withdrawal symptoms, often with limited success.
• For ALD, treatment options are even more limited, often involving lifestyle changes and management of complications.
• If pemvidutide proves effective in addressing both the underlying alcohol misuse and the associated liver damage, it could represent a significant advancement compared to existing therapies.
• Companies like Gilead and Intercept have been focused on liver diseases, but not specifically targeting ALD in conjunction with AUD, making Altimmune's approach potentially unique.

Stakeholder Impact

• Shareholders may react positively to the news of expanded indications for pemvidutide.
• Patients with AUD and ALD could benefit from a new treatment option if pemvidutide proves effective.
• The company's employees may be involved in the planning and execution of the clinical trials.

Next Steps

• Initiate Phase 2 clinical trial for pemvidutide in AUD patients in the second quarter of 2025.
• Initiate Phase 2 clinical trial for pemvidutide in ALD patients in the third quarter of 2025.
• Analyze data from the Phase 2 trials to determine the next steps in the development of pemvidutide for these indications.

Key Dates